[1] SIEGEL R L,MILLER K D,WAGL E N,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[2] ALYAHYA K A,ALARFAJ A A,ALYAHYA A A,et al.Indications and complications for surgical management of thyroid diseases:a single center experience[J].Ann Med Surg,2022,79:103980.
[3] HAUGEN B R,ALEXANDER E K,BIBLE K C,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.
[4] SLIJEPCEVIC N,ZIVALJEVIC V,DIKLIC A,et al.Risk factors associated with intrathyroid extension of thyroid microcarcinomas[J].Langenbecks Arch Surg,2018,403(5):615-622.
[5] TAGLIABUE M,GIUGLIANO G,MARIANI M C,et al.Prevalence of central compartment lymph node metastases in papillary thyroid micro-carcinoma:a retrospective evaluation of predictive preoperative features[J].Cancers,2021,13(23):6028.
[6] YU X M,WAN Y,SIPPEL R S,et al.Should all papillary thyroid microcarcinomas be aggressively treated? —an analysis of 18,445 cases[J].Ann Surg,2011,254(4):653-660.
[7] HADDAD R I,BISCHOFF L,BALL D,et al.Thyroid carcinoma,version 2.2022,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2022,20(8):925-951.
[8] YAO F,YANG Z,LI Y,et al.Real-world evidence on the sensitivity of preoperative ultrasound in evaluating central lymph node metastasis of papillary thyroid carcinoma[J].Front Endocrinol(Lausanne),2022,13:865911.
[9] LIU W,DONG Z,SU Y, et al.Risk probability model for residual metastatic lymph node in patients with papillary thyroid microcarcinoma undergoing cervical central lymph node dissection[J].Zhejiang Da Xue Xue Bao Yi Xue Ban,2021,50(6):722-729.
[10] YU Y,YU Z,LI M,et al.Model development to predict central lymph node metastasis in cn0 papillary thyroid microcarcinoma by machine learning[J].Ann Transl Med,2022,10(16):892.
[11] HENG Y,YANG Z,CAO P,et al.Lateral involvement in different sized papillary thyroid carcinomas patients with central lymph node metastasis:amulti-center analysis[J].J Clin Med,2022,11(17):4975.
[12] WEI X,MIN Y,FENG Y,et al.Development and validation of an individualized nomogram for predicting the high-volume(>5) central lymph node metastasis in papillary thyroid microcarcinoma[J].J Endocrinol Invest,2022,45(3):507-515.
[13] SU H,LI Y.Prophylactic central neck dissection and local recurrence in papillary thyroid microcarcinoma:a meta-analysis[J].Braz J Otorhinolar.2019,85(2):237-243.
[14] SCHERER H C,FERNANDES P M,SCHEFFEL R S,et al.Papillary thyroid microcarcinoma:insights from a cohort of 257 thyroidectomized patients[J].Horm Metab Res,2023,55(3):161-168.
[15] MA T,WANG L,ZHANG X,et al.Clinical and molecular pathology prediction model for central lymph node metastasis in cn0 papillary thyroid microcarcinoma[J].Front Endocrinol(Lausanne),2023,14:1075598.
[16] 杨瑞,张守鹏,黄韬,等.cN0期甲状腺微小乳头状癌淋巴结转移模型的构建和验证以及手术方式探讨[J].临床耳鼻咽喉头颈外科杂志,2021,35(2):137-140.
[17] ENEWOLD L,PARSONS H,ZHAO L,et al.Updated overview of the SEER-medicare data:enhanced content and applications[J].J Natl Cancer Inst Monogr,2020(55):3-13.
[18] WALGAMA E,SACKS W L,HO A S.Papillary thyroid microcarcinoma:optimal management versus overtreatment[J].Curr Opin Oncol,2020,32(1):1-6.
[19] SUGITANI I.Active surveillance of low-risk papillary thyroid microcarcinoma[J].Best Pract Res Clin Endocrinol Metab,2023,37(1):101630
[20] PERROS P,BOELAERT K,COLLEY S,et al.Guidelines for the management of thyroid cancer[J].Clin Endocrinol,2014,81(Suppl 1):1-122.
[21] GHARIB H,PAPINI E,GARBER J R,et al.American association of clinical endocrinologists,American college of endocrinology,and associazione medici endocrnologi guidelines for clinical practice for the diagnosis and management ofthyroid nodules—2016 update[J].Endocr Pract,2016,22(5):622-639.
[22] FACKELMAYER O J,WU J X,YEH M W.Endocrine surgery:management of postoperative complications following endocrine surgery of the neck[J].Sur Clin North Am,2021,101(5):767-784.
[23] Corrigendum to Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China(English version)[J].Chin J Can Res,2022,34(6):644.
[24] XUE T,LIU C,LIU J J,et al.Analysis of the relevance of the ultrasonographic features of papillary thyroid carcinoma and cervical lymph node metastasis on conventional and contrast-enhanced ultrasonography[J].Front Oncol,2021,11:794399.
[25] FENG J W,YE J,WU W X,et al.Management of cN0 papillary thyroid microcarcinoma patients according to risk-scoring model for central lymph node metastasis and predictors of recurrence[J].J Endocrinol Invest,2020;43(12):1807-1817.
[26] WANG Y,XIAO Y B,PAN Y,et al.The effectiveness and safety of prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma patients:a meta-analysis[J].FrontEndocrinol,2022,13:1094012.
[27] LIU W F,WANG S F,XIA X T.Risk factor analysis for central lymph node metastasis in papillary thyroid microcarcinoma[J].Int J Gen Med,2021,14:9923-9929.
[28] WANG D H,ZHU J,DENG C,et al.Preoperative and pathological predictive factors of central lymph node metastasis in papillary thyroid microcarcinoma[J].Auris Nasus Larynx,2022,49(4):690-696.
[29] ZHANG Q,WANG Z M,MENG X Y,et al.Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma(mPTC):a retrospective analysis of 1304 cases.[J].Asian J Surg,2019,42(4):571-576.
[30] 潘勐,黄勇,汪汉华,等.CT征象联合临床病理特征对甲状腺微小乳头状癌中央组淋巴结转移的预测价值[J].中国普外基础与临床杂志,2022,29(6):738-742.
[31] TUTTLE R M,HAUGEN B,PERRIER N D.Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer(Eighth Edition):What changed and why?[J].Thyroid,2017,27(6):751-756.
[32] SEIFERT R,SCHÄFERS M A S,HEITPLATZ B,et al.Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases[J].J Nucl Med,2021,62(12):1702-1709.
[33] 李洪跃,徐先发,杨晓琦,等.基于血清代谢标志物的甲状腺癌患者淋巴结转移风险的预测模型[J].现代医学,2022,50(5):581-588. |